B. Riley analyst Mayank Mamtani lowered the firm’s price target on Vaxart (VXRT) to $2 from $2.50 and keeps a Buy rating on the shares. The Q4 ...

B. Riley analyst Mayank Mamtani raised the firm’s price target on Trevi Therapeutics (TRVI) to $20 from $11 and keeps a Buy rating on the ...

Lisa Ricciardi; President, Chief Executive Officer, Director; Cognition Therapeutics Inc. John Doyle; Chief Fi ...

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Cytokinetics (CYTK – Research Report), with a price target of $88.00. The company’s shares closed ...

Mayank Mamtani; Analyst; B. Riley Securities, Inc. Good morning, and welcome to Agenus Inc.'s fourth-quarter and year-end 2024 earnings conference call. (Operator Instructions) As a reminder ...

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report), with ...

B. Riley analyst Mayank Mamtani reiterates a Buy rating on Viking Therapeutics (VKTX) with a $96 price target after the company announced a “long-awaited” manufacturing agreement with ...

Trevi Therapeutics (TRVI) stock has rocketed up over 63% in the past week on news that recent clinical trials have shown promising results. The ...

Hello, everyone, and welcome to MiNK Therapeutics fourth-quarter 2024 financial results call. Please note that this call is being recorded. (Operator Instructions) I'd now like to hand the call over ...